Cytosorbents (CTSO) Current Deferred Revenue (2013 - 2026)
Cytosorbents (CTSO) posted Current Deferred Revenue of $34000.0 for Q1 2026, down 81.32% on a QoQ basis from $182000.0 in Q4 2025, and down 93.77% year-over-year from $546028.0 in Q1 2025.
Cytosorbents (CTSO) Current Deferred Revenue (2013 - 2026) Analysis & Trends
Cytosorbents' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $34000.0 for Q1 2026.
- Quarterly Current Deferred Revenue fell 93.77% year-over-year to $34000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34000.0 (down 93.77% YoY) and the FY2025 annual result came in at $182000.0, down 69.46% from the prior year.
- Current Deferred Revenue was $34000.0 for Q1 2026 at Cytosorbents, down from $182000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.5 million in Q4 2022 and bottomed at $34000.0 in Q1 2026.
- A 5-year average of $627452.6 and a median of $474514.0 in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue slipped 8.96% — and 2026, when it slumped 93.77%.
- Cytosorbents' Current Deferred Revenue stood at $1.5 million in 2022, then fell by 8.96% to $1.4 million in 2023, then plunged by 56.84% to $596000.0 in 2024, then slumped by 69.46% to $182000.0 in 2025, then sank by 81.32% to $34000.0 in 2026.
- Business Quant data shows CTSO's Current Deferred Revenue at $34000.0 in Q1 2026, $182000.0 in Q4 2025, and $403000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 182,000.00 |
| Sep 30, 2025 | 403,000.00 |
| Jun 30, 2025 | 361,000.00 |
| Mar 31, 2025 | 546,028.00 |
| Dec 31, 2024 | 596,000.00 |
| Dec 31, 2023 | 1.38 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Dec 31, 2021 | 1.95 Mn |
| Dec 31, 2020 | 728,351.00 |
| Dec 31, 2014 | 833.00 |
| Sep 30, 2014 | 3,333.00 |
| Jun 30, 2014 | 5,833.00 |
| Mar 31, 2014 | 117,364.00 |
| Dec 31, 2013 | 272,359.00 |
| Sep 30, 2013 | 435,686.00 |